NCT05915247View on ClinicalTrials.gov

Single Ascending Doses of HER-096 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

March 29, 2023

Primary Completion Date

September 29, 2023

Study Completion Date

September 29, 2023

Conditions
Parkinson Disease
Interventions
DRUG

HER-096

Administered as a single dose via s.c. injection

DRUG

Placebo

Administered as a single dose via s.c. injection

Trial Locations (1)

Unknown

Clinical Research Services Turku - CRST Oy, Turku

Sponsors
All Listed Sponsors
collaborator

Clinical Research Services Turku - CRST Oy

UNKNOWN

lead

Herantis Pharma Plc.

INDUSTRY

NCT05915247 - Single Ascending Doses of HER-096 in Healthy Subjects | Biotech Hunter | Biotech Hunter